Developing a first-in-class autoregulation technology to create safer drugs

About us

Novalgen is a clinical-stage company, revolutionizing the immunology landscape with its innovative autoregulation technology. Our focus is on the next generation of multi-specific antibodies to generate transformative outcomes in autoimmune, oncological, and other immunological disorders.

Our strategy

Our technologies

We are changing the paradigm of immunotherapies with our autoregulation platform technology. This groundbreaking approach integrates self-regulating capabilities into a range of immunotherapies tailored to improve clinical outcomes in patients.

Our technologies


To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.

Read more